Grifols just printed its Q3 2026 report and the story is not the share price. The stock closed at €11.23 on 3 November, well below a stated cash flow value estimate of €36.08, even as the plasma giant delivered adjusted EBITDA of €538m with a 26.4% margin and net leverage of about 3.98x. This is a sentiment clash. Recent buyers have chased a short streak of gains, while the core numbers point to an earnings release dominated by one question: whether the balance sheet strain justifies this kind of valuation gap.
We like Grifols' 26.4% EBITDA margin but are uneasy about a near 4x net leverage ratio and the gap between its price and stated cash flow value. You can compare this setup with companies that pair solid profitability with stronger balance sheets in our list of solid balance sheet and fundamentals stocks (196 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):€2,040m vs. €1,865.4m (up about 9.4%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):€189m vs. €126.965m (up about 48.9%)
-
Basic EPS (Q3 2026 vs. Q2 2026):€0.2777 vs. €0.2263 (up about 22.7%)
-
Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025):26.4% vs. 25.8% (about 60 bps improvement)
Tired of scrolling through dense earnings tables and walls of text on Grifols? Get a clear visual view of the stock's valuation story in the company report for Grifols. .
Grifols Bull Case Hinges On Execution Milestones
The bullish story around Grifols is built on operational follow through rather than just higher plasma volumes.
"The main thing that has to go right is continued execution on plasma self sufficiency, cost discipline and debt reduction so that free cash flow and adjusted EBITDA margins stay aligned with the multi year targets management has set."
Q3 points to progress on that checklist. Adjusted EBITDA margin reached 26.4% while the year to date level is 24.8% against a 25% full year goal. Free cash flow before M&A is €298m year to date and management still expects to hit 2026 targets. Net leverage is around 3.98x, now inside the credit agreement ceiling.
One Narrative disagrees with today's price. → See where this Narrative says Grifols should trade .
Grifols Bear Case: Cash Flow Fears Partly Intact
The harsher view on Grifols centers on whether cash generation can really keep up with regulatory and pricing friction.
"While free cash flow before M&A reached €468 million in 2025 and remained positive at €91 million in H1 2026, any reversal of this trend due to sustained regulatory disruption in Canada, ongoing albumin price pressure in China or higher compliance costs around plasma collection could stall deleveraging, keep interest costs elevated and weigh on future earnings quality."
Q3 shows that concern is only partly answered. Free cash flow before M&A is €298m year to date and net leverage is just under 4x, so deleveraging is progressing. Yet albumin weakness in China persists and management still flags that market as a key risk, which means the feared drag on earnings quality has not been fully cleared.
Hunt Valuation Disconnects With Care
Grifols shows how solid adjustments on margins and leverage can still coexist with a debate over value. The real opportunity is finding stocks that could be undervalued before the market corrects them.
-
Company 1 - 38% below our estimate - uses new funding to ramp high horsepower engine capacity for data center clients.
-
Company 2 - 36% below our estimate - converts major AI infrastructure and multicloud database agreements into subscription-heavy workloads on its platforms.
-
Company 3 - 44% below our estimate - expands AI targeted power and rack capacity so cloud customers can address data center constraints.
That is three of the list. See the full list of 195 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GRF.MC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
